EP2970395A4 - Verfahren und zusammensetzungen für norovirus-blockadeepitope - Google Patents

Verfahren und zusammensetzungen für norovirus-blockadeepitope Download PDF

Info

Publication number
EP2970395A4
EP2970395A4 EP14764479.3A EP14764479A EP2970395A4 EP 2970395 A4 EP2970395 A4 EP 2970395A4 EP 14764479 A EP14764479 A EP 14764479A EP 2970395 A4 EP2970395 A4 EP 2970395A4
Authority
EP
European Patent Office
Prior art keywords
norovirus
blockade
epitopes
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14764479.3A
Other languages
English (en)
French (fr)
Other versions
EP2970395A2 (de
Inventor
Ralph Steven BARIC
Lisa Chon LINDESMITH
Kari Moore DEBBINK
Eric Francis DONALDSON
Jesica Anne SWANSTROM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of EP2970395A2 publication Critical patent/EP2970395A2/de
Publication of EP2970395A4 publication Critical patent/EP2970395A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
EP14764479.3A 2013-03-15 2014-03-15 Verfahren und zusammensetzungen für norovirus-blockadeepitope Withdrawn EP2970395A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798946P 2013-03-15 2013-03-15
US201361887101P 2013-10-04 2013-10-04
PCT/US2014/029969 WO2014145245A2 (en) 2013-03-15 2014-03-15 Methods and compositions for norovirus blockade epitopes

Publications (2)

Publication Number Publication Date
EP2970395A2 EP2970395A2 (de) 2016-01-20
EP2970395A4 true EP2970395A4 (de) 2017-03-29

Family

ID=51538440

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14764479.3A Withdrawn EP2970395A4 (de) 2013-03-15 2014-03-15 Verfahren und zusammensetzungen für norovirus-blockadeepitope

Country Status (2)

Country Link
EP (1) EP2970395A4 (de)
WO (1) WO2014145245A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019079594A1 (en) * 2017-10-18 2019-04-25 The University Of North Carolina At Chapel Hill METHODS AND COMPOSITIONS FOR VACCINES AGAINST NOVOVIRUS AND DIAGNOSIS OF NOVOVIRUS
US11759512B2 (en) * 2018-07-13 2023-09-19 Medicago Inc. Modified norovirus VP1 proteins and VLPs comprising modified norovirus VP1 proteins
CN114316009B (zh) * 2020-09-29 2023-04-25 上海交通大学 一种能够结合多种病毒的蛋白及其应用
CN113336861B (zh) * 2021-06-16 2023-09-12 郑州市第六人民医院 一种以诺如病毒vp1蛋白为载体的嵌合蛋白及其制备方法及病毒样颗粒
WO2023009977A1 (en) * 2021-07-26 2023-02-02 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus chimeric therapeutics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2066354T3 (da) * 2006-09-29 2013-05-27 Ligocyte Pharmaceuticals Inc Norovirus vaccine formuleringer
WO2011091279A2 (en) * 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles
EP2591097A1 (de) * 2010-07-06 2013-05-15 Novartis AG Immunogene zusammensetzungen aus norovirus und verfahren

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 22 December 2006 (2006-12-22), "Norovirus Hu/GII.4/DenHaag89/2006/NL capsid", retrieved from EBI accession no. EMBL:ABL74395 *
DATABASE EMBL [online] 29 April 2004 (2004-04-29), "Norovirus Hu/NLV/Oxford/B5S13/2002/UK capsid protein", retrieved from EBI accession no. EMBL:AAT00339 *
DATABASE UniProt [online] 1 March 2002 (2002-03-01), "SubName: Full=Capsid protein {ECO:0000313|EMBL:AAK50355.1};", retrieved from EBI accession no. UNIPROT:Q8V0P2 Database accession no. Q8V0P2 *
DATABASE UniProt [online] 5 July 2004 (2004-07-05), "SubName: Full=Capsid protein {ECO:0000313|EMBL:AAR97648.1};", retrieved from EBI accession no. UNIPROT:Q6REW7 Database accession no. Q6REW7 *
GREEN K Y ET AL: "A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly", JOURNAL OF INFECTIOUS DISEASES. JID, UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, vol. 185, no. 2, 15 January 2002 (2002-01-15), pages 133 - 146, XP002253162, ISSN: 0022-1899, DOI: 10.1086/338365 *
J. J. SIEBENGA ET AL: "Epochal Evolution of GGII.4 Norovirus Capsid Proteins from 1995 to 2006", JOURNAL OF VIROLOGY., vol. 81, no. 18, 3 July 2007 (2007-07-03), US, pages 9932 - 9941, XP055345077, ISSN: 0022-538X, DOI: 10.1128/JVI.00674-07 *
K. DEBBINK ET AL: "Chimeric GII.4 Norovirus Virus-Like-Particle-Based Vaccines Induce Broadly Blocking Immune Responses", JOURNAL OF VIROLOGY., vol. 88, no. 13, 16 April 2014 (2014-04-16), US, pages 7256 - 7266, XP055306276, ISSN: 0022-538X, DOI: 10.1128/JVI.00785-14 *
K. E. DINGLE: "Mutation in a Lordsdale Norovirus Epidemic Strain as a Potential Indicator of Transmission Routes", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 42, no. 9, 1 September 2004 (2004-09-01), US, pages 3950 - 3957, XP055345046, ISSN: 0095-1137, DOI: 10.1128/JCM.42.9.3950-3957.2004 *
KIM M C ET AL: "Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 21, no. 2, 1 February 2013 (2013-02-01), pages 485 - 492, XP002757485, ISSN: 1525-0024, [retrieved on 20121218], DOI: 10.1038/MT.2012.246 *
LINDESMITH LISA C ET AL: "Immunogenetic mechanisms driving norovirus GII.4 antigenic variation.", PLOS PATHOGENS 2012, vol. 8, no. 5, 2012, pages e1002705, XP002762429, ISSN: 1553-7374 *
ZHENG D P ET AL: "Norovirus classification and proposed strain nomenclature", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 346, no. 2, 15 March 2006 (2006-03-15), pages 312 - 323, XP024896729, ISSN: 0042-6822, [retrieved on 20060315], DOI: 10.1016/J.VIROL.2005.11.015 *

Also Published As

Publication number Publication date
WO2014145245A2 (en) 2014-09-18
EP2970395A2 (de) 2016-01-20
WO2014145245A3 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
HK1224218A1 (zh) 穩定的抗體組合物
EP3080725A4 (de) Anwendungssynchornization
EP2992097A4 (de) Zusammensetzungen und verfahren
EP2951283A4 (de) Zusammensetzungen und verfahren
EP3071295A4 (de) Antiinfektiöse verfahren, zusammensetzungen und vorrichtungen
EP3008155A4 (de) Bioraffinierungsverfahren
EP3068622A4 (de) Zusammensetzungen und verfahren zur herstellung eines geschmolzenen filaments
EP3020778A4 (de) Haftmittelzusammensetzung
EP3060919A4 (de) Verfahren und zusammensetzungen zur immunmodulation
EP3094785A4 (de) Hydrofissionsbarriere
EP3064513A4 (de) Polyrotaxanhaltige zusammensetzung
EP3085578A4 (de) Kopfstütze
EP3013361A4 (de) Zusammensetzungen und verfahren für die immuntherapie
EP3065550A4 (de) Verfahren und zusammensetzungen zur sepsis-behandlung
EP2970445A4 (de) Humanisierte anti-n2-antikörper
EP3075822A4 (de) Duftstoffzusammensetzung
EP3019665A4 (de) Strassenleitplanke
EP3075384A4 (de) Zusammensetzung gegen adipositas
EP3005906A4 (de) Kopfstütze
HK1223684A1 (zh) 改進抗體穩定性的方法
EP2970395A4 (de) Verfahren und zusammensetzungen für norovirus-blockadeepitope
ZA201601606B (en) Methods and compositions for improving kidney function
EP3033392A4 (de) Mechano-reaktive zusammensetzung
EP3065774A4 (de) Anti-ccl17-antikörper
HK1223300A1 (zh) 皮質類固醇組合物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151006

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DONALDSON, ERIC FRANCIS

Inventor name: BARIC, RALPH STEVEN

Inventor name: SWANSTROM, JESICA ANNE

Inventor name: LINDESMITH, LISA CHON

Inventor name: DEBBINK, KARI MOORE

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/08 20060101AFI20161005BHEP

Ipc: C12N 15/63 20060101ALI20161005BHEP

Ipc: C07K 16/10 20060101ALI20161005BHEP

Ipc: A61K 39/12 20060101ALI20161005BHEP

Ipc: C12N 7/01 20060101ALI20161005BHEP

Ipc: A61P 31/14 20060101ALI20161005BHEP

Ipc: C12N 15/40 20060101ALI20161005BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/12 20060101ALI20161020BHEP

Ipc: C12N 7/01 20060101ALI20161020BHEP

Ipc: C12N 15/40 20060101ALI20161020BHEP

Ipc: C12N 15/63 20060101ALI20161020BHEP

Ipc: C07K 16/10 20060101ALI20161020BHEP

Ipc: A61P 31/14 20060101ALI20161020BHEP

Ipc: C07K 14/08 20060101AFI20161020BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170228

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/63 20060101ALI20170222BHEP

Ipc: A61P 31/14 20060101ALI20170222BHEP

Ipc: A61K 39/12 20060101ALI20170222BHEP

Ipc: C07K 14/08 20060101AFI20170222BHEP

Ipc: C12N 15/40 20060101ALI20170222BHEP

Ipc: C12N 7/01 20060101ALI20170222BHEP

Ipc: C07K 16/10 20060101ALI20170222BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180615

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191001